Han Xiao

Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.

Han Xiao, Madhu Mazumdar, Dean F. Bajorin et al. · Journal of Clinical Oncology · 1997 · 83 citations

Medicine, Oncology, Surgery +17

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).

Michael J. Morris, Glenn Heller, Alan H. Bryce et al. · Journal of Clinical Oncology · 2019 · 45 citations

Medicine, Endocrinology, Pharmacology +17

A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m²for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Matthew G. Fury, Eric J. Sherman, Donna Lisa et al. · Journal of the National Comprehensive Cancer Network · 2012 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity‐modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma

Matthew G. Fury, Han Xiao, Eric J. Sherman et al. · Head & Neck · 2015 · 40 citations · Full text

Medicine, Oncology, Radiation Oncology +16

The Safety and Efficacy of Single-Agent Pemetrexed in Platinum-Resistant Advanced Urothelial Carcinoma: A Large Single-Institution Experience

Richard Bambury, David J. Benjamin, Joshua Chaim et al. · The Oncologist · 2015 · 39 citations · Full text

Medicine, Oncology, Pharmacotherapy +13